Join NETRF’s ‘Research Changes Lives’ Giving Tuesday Campaign—Every gift doubled now through December 3, 2024. LEARN MORE
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
NETRF’s 2024 Margie & Robert E. Petersen Neuroendocrine Tumor Research Symposium was held October 28-30 at The Hotel Commonwealth in Boston, Massachusetts. Our Symposium brought
The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) and NETRF are proud to announce that Dr. Ajay Kumar Sharma has been
A new study has revealed that certain bone marrow cells may absorb more radiation during radiopharmaceutical therapy (RPT) than previously believed. This finding could explain
The investigational drug cabozantinib (CABOMETYX®) has significantly improved outcomes for those living with advanced neuroendocrine tumors (NETs), according to the latest results from the Phase
A recent study has unveiled key molecular insights that could transform the treatment landscape for lung neuroendocrine tumors (NETs). The Neuroendocrine Tumor Research Foundation provided
Using PRRT with 177Lu-DOTATATE before surgery is both safe and effective for patients with non-functioning pancreatic neuroendocrine tumors and certain risk factors, according to the
The Think NENs Global Educational Program for Primary Care Physicians has been launched by the International Neuroendocrine Cancer Alliance (INCA). The Think NENs Global Educational
The Neuroendocrine Tumor Research Foundation (NETRF), in partnership with the North American Neuroendocrine Tumor Society (NANETS), is proud to announce Victor Santoro Fernandes, PhD, as
Neuroendocrine carcinomas (NECs) are uncommon and aggressive cancers with limited treatment options after the failure of platinum-based therapies. A recently concluded phase II trial investigated
The University of Pennsylvania is now enrolling patients in the new phase 1/2 multi-center clinical trial for CAR T cell therapy. The trial includes patients
